Next Article in Journal
Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases
Previous Article in Journal
Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease
Review

Sexually Transmitted Neisseria gonorrhoeae Infections—Update on Drug Treatment and Vaccine Development

1
School of Pharmacy, College of Pharmacy & Health Sciences, Campbell University, Buies Creek, NC 27506, USA
2
Department of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, Campbell University, Buies Creek, NC 27506, USA
*
Author to whom correspondence should be addressed.
Academic Editor: William Cho
Received: 18 December 2020 / Revised: 17 January 2021 / Accepted: 3 February 2021 / Published: 5 February 2021
(This article belongs to the Section New Drugs Exploration and Development)
Background: Sexually transmitted gonorrhea, caused by the Gram-negative diplococcus Neisseria gonorrhoeae, continues to be a serious global health challenge despite efforts to eradicate it. Multidrug resistance among clinical N. gonorrhoeae isolates has limited treatment options, and attempts to develop vaccines have not been successful. Methods: A search of published literature was conducted, and information extracted to provide an update on the status of therapeutics and vaccine development for gonorrheal infection. Results: Recommended pharmacological treatment for gonorrhea has changed multiple times due to increasing acquisition of resistance to existing antibiotics by N. gonorrhoeae. Only broad-spectrum cephalosporin-based combination therapies are currently recommended for treatment of uncomplicated urogenital and anorectal gonococcal infections. With the reported emergence of ceftriaxone resistance, successful strategies addressing the global burden of gonorrhea must include vaccination. Century-old efforts at developing an effective vaccine against gonorrhea, leading to only four clinical trials, have not yielded any successful vaccine. Conclusions: While it is important to continue to explore new drugs for the treatment of gonorrhea, the historical trend of resistance acquisition suggests that any long-term strategy should include vaccine development. Advanced technologies in proteomics and in silico approaches to vaccine target identification may provide templates for future success. View Full-Text
Keywords: gonorrhea; Neisseria gonorrhoeae; multidrug resistance; ceftriaxone; azithromycin; proteomics-driven vaccine antigen discovery; in silico approaches to vaccine antigen identification; vaccine development gonorrhea; Neisseria gonorrhoeae; multidrug resistance; ceftriaxone; azithromycin; proteomics-driven vaccine antigen discovery; in silico approaches to vaccine antigen identification; vaccine development
Show Figures

Figure 1

MDPI and ACS Style

Jefferson, A.; Smith, A.; Fasinu, P.S.; Thompson, D.K. Sexually Transmitted Neisseria gonorrhoeae Infections—Update on Drug Treatment and Vaccine Development. Medicines 2021, 8, 11. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020011

AMA Style

Jefferson A, Smith A, Fasinu PS, Thompson DK. Sexually Transmitted Neisseria gonorrhoeae Infections—Update on Drug Treatment and Vaccine Development. Medicines. 2021; 8(2):11. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020011

Chicago/Turabian Style

Jefferson, Amber, Amanda Smith, Pius S. Fasinu, and Dorothea K. Thompson 2021. "Sexually Transmitted Neisseria gonorrhoeae Infections—Update on Drug Treatment and Vaccine Development" Medicines 8, no. 2: 11. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020011

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop